What Is a Compound Library? Focused, Diverse, Natural-Product, and Approved-Drug Libraries
9 min read••By Chemical Express Thailand

Choosing the wrong collection to screen first wastes budget, stalls timelines, and produces hits you cannot follow up. The decision between focused, diverse, natural-product, and approved-drug sets depends on your biology, throughput, and downstream chemistry needs. This article explains what a compound library is, how each type works in practice, and how to evaluate quality before you commit to a screen.
What is a compound library in drug discovery?
A compound library is a curated set of small molecules prepared for high-throughput or medium-throughput screening. Libraries are typically supplied in DMSO, formatted into barcoded 96-well, 384-well, or 1536-well plates, and delivered with plate maps and structure data files (SD or SDF) for tracking. The goal is systematic, reproducible screening that surfaces tractable hits with workable follow-up chemistry.
Four main library types serve different discovery purposes. Focused libraries cluster around a target class or pharmacophore. Diverse libraries span broad chemical space. Natural-product libraries provide complex, 3D-rich scaffolds. Approved-drug libraries support repurposing campaigns and assay benchmarking. Each type fits different stages of discovery and different levels of target knowledge.
Libraries support both target-based and phenotypic assay formats. Pairing a well-curated compound set with robust controls, a sound replicate strategy, and complete structure tracking separates a productive screen from one that generates noise.
How compound library screening works, from assay design to hit triage
Planning the screen
Start by defining the biological question clearly. Then choose an assay format and readout, and match library size to your actual throughput capacity. Build plate maps with positive and negative controls before the first plate runs.
Run a pilot screen first. Use a small subset (200 to 500 compounds) to verify the Z' factor, signal window, and any optical or chemical interference risks. A pilot catches assay problems cheaply, before they affect thousands of compounds.
Assay formats and readouts
Common readouts include absorbance, fluorescence intensity, time-resolved fluorescence, luminescence, and high-content imaging. Each offers different sensitivity and dynamic range. The choice depends on the assay biology and the available instrumentation.
Flag optical interference and redox reactivity early. Fluorescent compounds, redox cyclers, and aggregators can mimic activity across multiple readout modes. Running an orthogonal counterscreen is the standard way to separate genuine hits from artifacts.
Confirming and triaging hits
After primary screening, confirm actives using fresh solids or independent aliquots, not the same stock. Run orthogonal assays and counterscreens to remove assay artifacts. Prioritize confirmed hits by potency, structural novelty, and feasibility of follow-up chemistry.
Use secondary assays to probe mechanism or flag liabilities. Evaluate ADME or pathway impact where needed. Metabolism assay kits covering key metabolic pathways, such as those available through Merck's biochemicals portfolio, can support early liability profiling without building a custom assay from scratch.
Quick tips
- Pre-warm and equilibrate plates to ambient temperature before opening to prevent condensation.
- Minimize freeze-thaw cycles; aliquot stocks at the start of a campaign.
- Randomize compound positions across plates to reduce systematic edge effects.
- Verify control stability across the full run, not just at the start.
- Track every plate with barcodes and audit logs to enable retrospective troubleshooting.
Focused, diverse, natural-product, and approved-drug libraries: structure, scope, and sourcing
How each library type is built
Focused libraries cluster compounds around a specific target class, binding pharmacophore, or chemical motif. When you already know a ligandable site or a chemotype that modulates your target family, a focused set raises hit rates and accelerates early SAR. The trade-off is reduced coverage of novel chemical space.
Diverse libraries maximize scaffold coverage by applying diversity metrics during design. Bemis-Murcko framework analysis, Tanimoto similarity thresholds, and physicochemical filters (Lipinski, Veber rules, PAINS removal) are applied to ensure the set represents broad, drug-like chemical space without redundant scaffolds. These sets are the standard starting point for phenotypic screens and novel biology.
Natural-product libraries provide 3D-rich scaffolds and polyfunctional motifs that synthetic compound sets rarely replicate. The structural complexity can seed unique SAR and reveal binding modes unavailable to flat, aromatic-heavy compound files. Solubility management requires attention: many natural-product scaffolds are less soluble than typical medicinal chemistry compounds.
Approved-drug libraries contain compounds with known safety, pharmacokinetic, and target data. They enable repurposing screens and serve as benchmarking tools during assay development. Known actives in the set produce expected phenotypes and provide reliable positive controls during assay validation.
Library types at a glance
| Type | Typical Size | Design Rationale | Pros | Trade-offs | Best-fit Assays | Plate Format | QC Notes |
|---|---|---|---|---|---|---|---|
| Focused | 200 to 5,000 | Target class or pharmacophore clustering | Higher hit rates; faster early SAR | Limited chemical space coverage | Target-based enzymatic or binding assays | 96- or 384-well | Confirm purity per compound; verify pharmacophore fit |
| Diverse | 2,000 to 100,000+ | Scaffold diversity, physicochemical filters | Broad coverage; unbiased for novel targets | Lower hit rate per compound; larger logistical footprint | Phenotypic screens; novel biology | 384- or 1536-well | Apply Tanimoto, Lipinski, Veber, and PAINS filters |
| Natural Product | 500 to 10,000 | 3D scaffold richness; polyfunctional motifs | Unique binding modes; novel SAR seeds | Solubility challenges; complex sourcing | Phenotypic; target-agnostic; mechanism-of-action studies | 96- or 384-well | Monitor solubility; confirm structural integrity |
| Approved Drug | 1,000 to 3,000 | Known pharmacology and safety profiles | Fast translational path; built-in controls | IP constraints; limited novel chemistry | Repurposing; assay benchmarking; validation screens | 96- or 384-well | Verify identity against reference databases |
Customising and extending a core set
A standard library is a starting point, not a ceiling. Add reference ligands, tool compounds, and orthogonal chemotypes to build SAR context around early hits. Merck's chemistry and biochemicals portfolio, which spans building blocks, chemical biology tools, and metabolite compound libraries, provides a practical source for extending a focused set without building from scratch.
TCI's Pharmaceutical Development and Drug Discovery Research catalogue adds breadth across bioconjugation reagents, prodrug ingredients, and crude medicine ingredients for research use. These resources are particularly relevant when natural-product-inspired scaffolds or ADC linker chemistry are part of the design rationale.
When to choose each library and how to evaluate quality for your assay
Matching library type to your situation
If the target class is known and ligandable, a focused library gives faster SAR with a smaller screening footprint. If the biology is novel or the screen is phenotypic, start with a diverse set. Natural-product collections make sense when you need new binding modes or 3D shape diversity. Approved-drug sets are the pragmatic choice for repurposing goals or when you need reliable positive controls during assay development.
Quick decision guide: which library fits your campaign?
- Target class is known and ligandable
- Early SAR around a pharmacophore is the priority
- You want higher hit rates with fewer compounds
- Rapid analog synthesis is planned after hits
- Biology is novel or target is poorly characterised
- Phenotypic screen with no prior ligand data
- Broad coverage is needed to find any actives
- Unbiased scaffold exploration is the goal
- 3D scaffold novelty is a selection criterion
- Looking for binding modes unavailable in flat compound files
- Mechanism-of-action study needs structurally complex probes
- Unique SAR seeds are a priority over throughput
- Repurposing campaign against a validated target
- Assay benchmarking with known actives required
- Regulatory timeline favours known safety profiles
- Need positive controls with documented pharmacology
Evaluating supplier quality
Check purity and identity data per compound, not just batch-level averages. Confirm the salt or hydrate form, water content, solubility data, and the analytical method used (LC-MS, NMR, HPLC). Ask for delivery documentation that includes SD files, plate maps, and QC certificates.
Logistics matter as much as chemistry. Confirm plate density and format compatibility with your automation. Plan reformatting steps before the campaign starts, not after plates arrive.
Aligning with downstream medicinal chemistry
Before finalising library selection, confirm synthetic tractability. Check that close analogs are commercially available or synthesisable. Verify IP space to avoid advancing into protected chemotypes. These checks are most efficiently done at the library selection stage, not after hits are confirmed.
Summary and next steps
Choose a compound library that matches your biological question, assay readout, and throughput capacity. Validate the assay with controls and a pilot run before full screening. Address interference risks, DMSO tolerance, and logistics before the campaign starts.
Use focused sets for faster SAR when the target is defined. Use diverse sets for discovery breadth. Use natural-product collections for 3D novelty and unique binding modes. Use approved-drug sets for repurposing and benchmarking. The right starting point depends on what you already know, not on library size alone.
Plan QC, storage conditions, and validation assays early. Confirmed hits move more smoothly into SAR, ADME checks, and mechanism studies when the upstream data are clean and well-documented. Match library type to the problem you want to solve, verify the assay with solid controls, and handle plates carefully. Clear selection criteria and front-loaded QC give your first screen the best chance of producing confirmable hits and actionable SAR.
Frequently Asked Questions
Recommended Products
All products below are available through Chemical Express Thailand. Submit an inquiry for pricing, availability, or technical guidance.
Recommended Products Available at Chemical Express
We deliver a wide range of Drug Discovery Fundamentals products from Merck, TCI, MedChemExpress (MCE) and Elabscience and other international brands across Thailand. For any inquiry or purchase, fill out our Inquiry Form or chat with us instantly on Line.